Cilostazol, a selective type III phosphodiesterase inhibitor, decreases triglyceride and increases HDL cholesterol levels by increasing lipoprotein lipase activity in rats

Atherosclerosis

Volumn 152, Issue 2, 2000, Pages 299-305

  Tani, Takeshi ^a   Uehara, Kenji ^b   Sudo, Toshiki ^b   Marukawa, Keiko ^b   Yasuda, Yoshinobu ^a   Kimura, Yukio ^b  

^a OTSUKA PHARMACEUTICAL CO LTD   (Japan)

^b Thromb and Vasc Res Laboratory   (Japan)

Author keywords

Cilostazol; HDL cholesterol; Lipoprotein lipase; Triglyceride

Indexed keywords

CILOSTAZOL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPOPROTEIN LIPASE; PHOSPHODIESTERASE INHIBITOR; TRIACYLGLYCEROL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; ENZYME ACTIVITY; HEART; LIPID METABOLISM; NONHUMAN; PRIORITY JOURNAL; RAT; STREPTOZOCIN DIABETES; TRIACYLGLYCEROL BLOOD LEVEL;

ANIMALS; ANTICOAGULANTS; BLOOD GLUCOSE; CHOLESTEROL, HDL; DIABETES MELLITUS, EXPERIMENTAL; HEPARIN; LIPIDS; LIPOPROTEIN LIPASE; MYOCARDIUM; PHOSPHODIESTERASE INHIBITORS; PLATELET AGGREGATION INHIBITORS; RATS; RATS, WISTAR; TETRAZOLES; TRIGLYCERIDES;

EID: 0033821449     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0021-9150(99)00480-3     Document Type: Article

References (39)

1. Austin M.A. Plasma triglyceride and coronary heart disease. Arterioscler. Thromb. 11:1991;2-14.
2. 3 levels by lipoprotein lipase. Clin. Chim. Acta. 112:1981;325-332.
3. 2-like particles during lipolysis of very low density lipoproteins in vitro. Proc. Natl. Acad. Sci. USA. 75:1978;4519-4523.
4. Iglesias A., Contreras J.A., Martinez-Pardo M., Entrala A., Herrera E., Lasuncion M.A. Cholesterol ester transfer activity in lipoprotein lipase deficiency and other primary hypertriglyceridemias. Clin. Chim. Acta. 221:1993;73-89.
5. Haward B.V. Lipoprotein metabolism in diabetes mellitus. J. Lipid Res. 28:1987;613-628.
6. Hidaka H., Hayashi H., Kohri H., Kimura Y., Hosokawa T., Igawa T., Saitoh Y. Selective inhibitor of platelet cyclic adenosine monophosphate phosphodiesterase, cilostamide, inhibits platelet aggregation. J. Pharmacol. Exp. Ther. 211:1979;26-30.
7. Simpson A.W.M., Reeves M.L., Rink T.J. Effects of SK F94120, an inhibitor of cyclic nucleotide phosphodiesterase type III, on human platelets. Biochem. Pharmacol. 37:1988;2315-2320.
8. Kauffman R.F., Schenck K.W., Utterback B.G., Crowe V.G., Cohen M.L. In vitro vascular relaxation by new inotropic agents: relationship to phosphodiesterase inhibition and cyclic nucleotides. J. Pharmacol. Exp. Ther. 242:1987;864-872.
9. Tanaka T., Ishikawa T., Hagiwara M., Onoda K., Itoh H., Hidaka H. Effects of cilostazol, a selective cAMP phosphodiesterase inhibitor on the contraction of vascular smooth muscle. Pharmacology. 36:1988;313-320.
10. Farah A.E., Alousi A.A., Schwarz P.P. Jr. Positive inotropic agents. Annu. Rev. Pharmacol. Toxicol. 24:1984;275-328.
11. Weishaar R.E., Kobylarz-Singer D.C., Steffen R.P., Kaplan H.R. Subclasses of cyclic AMP-specific phosphodiesterase in left ventricular muscle and their involvement in regulating myocardial contractility. Circ. Res. 61:1987;539-547.
12. Pang S.C. Cyclic AMP and cyclic GMP phosphodiesterases: target for drug development. Drug Dev. Res. 12:1988;85-92.
13. Weishaar R.E., Michael H.C., Bristol A. A new generation of phosphodiesterase inhibitors: multiple molecular forms of phosphodiesterase and the potential for drug selectivity. J. Med. Chem. 28:1985;537-545.
14. Kimura Y., Tani T., Kanbe T., Watanabe K. Effect of cilostazol on platelet aggregation and experimental thrombosis. Arzneim.-Forsch. Drug Res. 35:1985;1144-1149.
15. Tani T., Sakurai K., Kimura Y., Ishikawa T., Hidaka H. Pharmacological manipulation of tissue cyclic AMP by inhibitors: Effects of phosphodiesterase inhibitors on the functions of platelets and vascular endothelial cells. Adv. Second Messenger Phosphoprotein Res. 25:1992;215-227.
16. Beavo J.A., Conti M., Heaslip R.J. Multiple cyclic nucleotide phosphodiesterases. Mol. Pharmacol. 46:1994;399-405.
17. Murase T., Yamada N., Ohsawa N., Kosaka K., Morita S., Yoshida S. Decline of postheparin plasma lipoprotein lipase in acromegalic patients. Metabolism. 29:1980;666-672.
18. Schotz M.C., Garfinkel A.S., Huebotter R.J., Stewart J.E. A rapid assay for lipoprotein lipase. J. Lipid Res. 11:1970;68-69.
19. Gent M, Easton JD, Hachinski V, Panak E, Sicurella J, Blakely JA. The Canadian American ticlopidine study (CATS) in thromboembolic stroke, Lancet 1989; 1215-1220.
20. Ridker P.M., Manson J.E., Buring J.E., Goldhaber S.Z., Hennekens C.H. The effect of chronic platelet inhibition with low-dose aspirin on atherosclerotic progression and acute thrombosis: clinical evidence from the Physicians' Health Study. Am. Heart J. 122:1991;1588-1592.
21. Tanaka N., Sakaguchi S., Oshige K., Niimura T., Kanehisa T. Effect of chronic administration of propranolol on lipoprotein composition. Metabolism. 25:1976;1071-1075.
22. Day J.L., Simpson N., Metcalfe J. Metabolic consequences of atenolol and propranolol in treatment of essential hypertension. Br. Med. J. 1:1979;77-80.
23. Grimm R.H. Jr, Leon A.S., Hunninghake D.B., Lenz K., Hannan P., Blackburn H. Effects of thiazide diuretics on plasma lipids and lipoproteins in mildly hypertensive patients. Ann. Intern. Med. 94:1981;7-11.
24. Helgeland A. The impact on serum lipids of combinations of diuretics and α-blockers and of β-blockers alone. J. Cardiovasc. Pharmacol. 6:(Suppl.):1984;S474-S476.
25. Elam M.B., Heckman J., Crouse J.R., Hunninghake D.B., Herd J.A., Davidson M., Gordon I.L., Bortey E.B., Forbes W.P. Effect of the novel antiplatelet agent cilostazol on plasma lipoproteins in patients with intermittent claudication. Arterioscler. Thromb. Vasc. Biol. 18:1998;1942-1947.
26. Dawson D.L., Cutler B.S., Meissner M.H., Strandness D.E. Jr. Cilostazol has beneficial effects in treatment of intermittent claudication. Results from a multicenter, randomized, prospective double-blind trial. Circulation. 98:1998;678-686.
27. Maeda E., Yoshino G., Nagata K., Matsuba K., Matsushita M., Sakurai K., Tani T., Kimura Y., Kazumi T. Effect of cilostazol on triglyceride metabolism in rats. Curr. Ther. Res. 54:1993;420-424.
28. Barter P., Rye K.A. Cholesterol ester transfer proteins: its role in plasma lipid transport. Clin. Exp. Pharmacol. Physiol. 21:1994;663-672.
29. Tall A.R. Plasma lipid transfer proteins. J. Lipid Res. 27:1986;361-367.
30. Akiyama H., Kudo S., Shimizu T. The absorption, distribution and excretion of a new antithrombotic and vasodilating agent, cilostazol, in rat, rabbit, dog and man. Arzneim.-Forsch. Drug Res. 35:1985;1124-1132.
31. Tsutsumi K., Inoue Y., Shima A., Iwasaki K., Kawamura M., Murase T. The novel compound NO-1886 increases lipoprotein lipase activity with resulting elevation of high density lipoprotein cholesterol, and long-term administration inhibits atherogenesis in the coronary arteries of rats with experimental atherosclerosis. J. Clin. Invest. 92:1993;411-417.
32. Ong J.M., Kirchgessner T.G., Schotz M.C., Kern P.A. Insulin increases the synthetic rate and messenger RNA level of lipoprotein lipase in isolated rat adipocytes. J. Biol. Chem. 263:1988;12933-12938.
33. Nikkila E.A. Plasma lipid and lipoprotein abnormalities in diabetes. Jarrett R.J. Diabetes and Heart Disease. 1984;133-167 Elsevier, Amsterdam.
34. Friedman G., Chajek-Shaul T., Stein O., Nue L., Etienne J., Stein Y. β-adrenergic stimulation enhances translocation, processing and synthesis of lipoprotein lipase in rat heart cells. Biochim. Biophys. Acta. 877:1986;112-120.
35. Carneheim C., Nedergaard J., Cannon B. Cold-induced beta-adrenergic recruitment of lipoprotein lipase in brown fat is due to increased transcription. Am. J. Physiol. 254:(2 Pt. 1):1988;E155-E161.
36. 1 heart-cell cultures. Biochim. Biophys. Acta. 1137:1992;237-241.
37. Peinado-Onsurbe J., Staels B., Deeb S., Auwerx J. Lipoprotein lipase expression in undifferentiated hepatoma cells is regulated by progesterone and protein kinase A. Biochemistry. 31:1992;10121-10128.
38. Nicholson C.D., Challiss R.A.J., Shahid M. Differential modulation of tissue function and therapeutic potential of selective inhibitors of cyclic nucleotide phosphodiesterase isozymes. TiPS. 12:1991;19-27.
39. Thompson W.J. Cyclic nucleotide phosphodiesterases: pharmacology, biochemistry and function. Pharm. Ther. 51:1991;13-33.